Company Overview and News

CV Check $2.5m share sale

Online resume screening company CV Check’s largest shareholder has sold off $2.5 million worth of shares in an effort to improve liquidity and allow new investors into the company.

CV Check Ltd to provide worker safety checks for New Zealand ministries

CV Check Ltd (ASX:CV1) has been selected to provide worker safety checks for people who work with children, by the New Zealand Ministries of Health, Education, and Social Development. The Vulnerable Children Act 2014 requires all paid people who work with children for government-funded organisations to be safety checked, and to have these safety checks updated every three years. To meet this need, CV Check has been appointed as the exclusive provider of a cross agency independent safety checking service.

CV Check Ltd to increase cash balance for growth

CV Check Ltd (ASX:CV1) is heading to market with a capital raising, and the ASX has granted the company a trading halt pending details. CV Check is focused on growing revenue streams by providing police checks, employment screening and tenant checks to employers, industry associations and individuals The halt will remain in place until the opening of trade on Tuesday 26th July 2016, or earlier if an announcement is made to the market.

CV Check Ltd verifies NZ acquisition and cash raising

CV Check Ltd (ASX:CV1) is on track to complete a $4.3 million share placement by the end of July and wrap up the acquisition of Resumé Check, a New Zealand based screening and verification business. The acquisition of Resumé Check will cost $1.51 million as well as performance based payments. CV Check's expansion into the New Zealand market will see it the group providing police checks, employment screening and tenant checks for employers and individuals.

CV Check Ltd granted ASX trading halt

CV Check Ltd (ASX:CV1) is heading to market with a capital raising, and the ASX has granted the company a trading halt to prepare. The halt will remain in place until the opening of trade on Friday 27th May 2016, or earlier if an announcement is made to the market.

CV Check Quarterly Update


Change of Company Secretary


CVCheck Review of Operations


CV Check to lock step growth in corporate sector

Proactive Investors is a global leader in financial news, media, research and events focusing on emerging growth companies across four continents.

Change of Address Details


Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

20h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

20h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...